Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
The Japanese government on October 29 signed off on a three-way deal with Takeda Pharmaceutical and Moderna to purchase 50 million doses of the US company’s COVID-19 vaccine, which would cover 25 million people, starting in the first half of…
To read the full story
Related Article
- Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
REGULATORY
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- DPP’s Tamaki Rails Against Govt’s Price Revision Decision
December 26, 2024
- Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
December 26, 2024
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…